468 results on '"Blanchet, Benoit"'
Search Results
2. Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients
3. Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care
4. Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection
5. Predictive factors associated with pemetrexed acute toxicity
6. The potential of microbiota information to better predict efficiency traits in growing pigs fed a conventional and a high-fiber diet
7. Hydroxychloroquine sulfate: A novel treatment for lipin-1 deficiency?
8. Decrease in anticortisolic drmg osilodrostat plasma exposure in patients treated with mitotane for adrenocortical carcinoma
9. Gut microbiota and host genetics contribute to the phenotypic variation of digestive and feed efficiency traits in growing pigs fed a conventional and a high fiber diet
10. Prevalence of drug–drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management
11. Quantification of nivolumab in human plasma by LC-MS/HRMS and LC-MS/MS, comparison with ELISA
12. Improving olaparib exposure to optimize adverse effects management.
13. Population Pharmacokinetics of Erlotinib in Patients With Non–small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients
14. Decrease in anticortisolic drug osilodrostat plasma exposure in patients treated with mitotane for an adrenocortical carcinoma
15. Pharmacokinetics/Pharmacodynamics of dabrafenib and trametinib for redifferentiation and treatment of radioactive-iodine-resistant mutated advanced differentiated thyroid cancer
16. Effects of acyl-coenzyme A binding protein (ACBP)/diazepam-binding inhibitor (DBI) on body mass index
17. Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant Recipients
18. Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences
19. Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection.
20. Association Between Plasma Rituximab Concentration and the Risk of Major Relapse in Antineutrophil Cytoplasmic Antibody–Associated Vasculitides During Rituximab Maintenance Therapy
21. Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib
22. Effects of Osilodrostat and Metyrapone on steroidogenesis in adrenocortical H295R tumor cells in vitro
23. LC-MS/MS method for simultaneous quantification of osilodrostat and metyrapone in human plasma from patients treated for Cushing’s Syndrome
24. Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients
25. Intra-individual dose escalation of abiraterone (ABI) according to its plasma exposure in patients (pts) with progressive metastatic castration-resistant prostate cancer (mRCPC): Results of the OPTIMABI trial.
26. Exposure toxicity and response relationship of cabozantinib (CABO) in patients with metastatic renal cell carcinoma (mRCC).
27. Cardiac toxicity associated with pharmacokinetic drug–drug interaction between crizotinib and sofosbuvir/velpatasvir: A case report
28. Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer
29. High plasma concentrations of acyl‐coenzyme A binding protein ( ACBP ) predispose to cardiovascular disease: Evidence for a phylogenetically conserved proaging function of ACBP
30. Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells
31. Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma
32. Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer
33. Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma
34. Potential drug–drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France
35. Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old
36. Low-dose mycophenolate mofetil improves survival in a murine model of Staphylococcus aureus sepsis by increasing bacterial clearance and phagocyte function
37. Cardiac toxicity associated with pharmacokinetic drug–drug interaction between crizotinib and sofosbuvir/velpatasvir: a case report
38. Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer
39. Abstract 1144: A multiplex LC-MS/MS method for assaying mAbs in oncology: Application to the CETUXIMAX GPCO-Unicancer trial on cetuximab pharmacokinetics in head and neck cancer patients
40. Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients
41. Quantification of infliximab and adalimumab in human plasma by a liquid chromatography tandem mass spectrometry kit and comparison with two ELISA methods
42. Drug interactions with solid tumour-targeted therapies
43. Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study
44. HPLC-MSMS steroidogenic profiles in ACTH-dependent Cushing Syndrome patients treated by osilodrostat or metyrapone suggest differences in the spectrum of steroidogenic enzyme inhibition between the two CYP11B1 inhibitors in clinical care
45. Additional file 1 of Gut microbiota and host genetics contribute to the phenotypic variation of digestive and feed efficiency traits in growing pigs fed a conventional and a high fiber diet
46. Additional file 2 of Gut microbiota and host genetics contribute to the phenotypic variation of digestive and feed efficiency traits in growing pigs fed a conventional and a high fiber diet
47. Can microbial data improve prediction of breeding values of efficiency traits in pigs fed conventional or fiber diets?
48. In utero heat stress and post-natal feeding behaviour, growth and carcass performance in pigs
49. High plasma concentrations of acyl‐coenzyme A binding protein (ACBP) predispose to cardiovascular disease: Evidence for a phylogenetically conserved proaging function of ACBP.
50. Microbiome and genetic contribution to the phenotypic variation of digestive efficiency in pig
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.